WO2019118766A2 - Cancer vaccines targeting survivin and uses thereof - Google Patents

Cancer vaccines targeting survivin and uses thereof Download PDF

Info

Publication number
WO2019118766A2
WO2019118766A2 PCT/US2018/065529 US2018065529W WO2019118766A2 WO 2019118766 A2 WO2019118766 A2 WO 2019118766A2 US 2018065529 W US2018065529 W US 2018065529W WO 2019118766 A2 WO2019118766 A2 WO 2019118766A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleic acid
acid sequence
fragment
survivin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/065529
Other languages
English (en)
French (fr)
Other versions
WO2019118766A3 (en
Inventor
Jian Yan
Anna SLAGER
Bradley GARMAN
Neil COOCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2020006285A priority Critical patent/MX2020006285A/es
Priority to RU2020122872A priority patent/RU2751253C1/ru
Priority to BR112020011820-6A priority patent/BR112020011820A2/pt
Priority to CA3083534A priority patent/CA3083534A1/en
Priority to JP2020532715A priority patent/JP7385569B2/ja
Priority to EP18889469.5A priority patent/EP3723793A4/en
Priority to KR1020247008261A priority patent/KR20240038139A/ko
Priority to CN201880080439.6A priority patent/CN111479583A/zh
Priority to AU2018383664A priority patent/AU2018383664B2/en
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Priority to KR1020207019758A priority patent/KR102648079B1/ko
Publication of WO2019118766A2 publication Critical patent/WO2019118766A2/en
Publication of WO2019118766A3 publication Critical patent/WO2019118766A3/en
Anticipated expiration legal-status Critical
Priority to MX2025004799A priority patent/MX2025004799A/es
Priority to JP2023125566A priority patent/JP7659599B2/ja
Priority to AU2024264712A priority patent/AU2024264712A1/en
Priority to JP2025056239A priority patent/JP2025092647A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Definitions

  • Nucleic acid molecules comprising one or more nucleic acid sequences selected from the group consisting of: (a) a nucleic acid sequence that encodes amino acids 19-159 of SEQ ID NO:2; (b) a nucleic acid sequence that encodes amino acids 19-210 of SEQ ID NO:4;
  • nucleic acid sequence that encodes amino acids 19-232 of SEQ ID NO:8 (c) a nucleic acid sequence that encodes amino acids 19-232 of SEQ ID NO:8; (d) a nucleic acid sequence that encodes a fragment comprising at least 90% of an entire length of amino acids 19- 159 of SEQ ID NO:2; (e) a nucleic acid sequence that encodes a fragment comprising at least 90% of an entire length of amino acids 19-210 of SEQ ID NO:4; (f) a nucleic acid sequence that encodes a fragment comprising at least 90% of an entire length of amino acids 19-232 of SEQ ID NO:8; (g) a nucleic acid sequence that encodes a protein that is at least 95% identical to amino acids 19-159 of SEQ ID NO:2; (h) a nucleic acid sequence that encodes a protein that is at least 95% identical to amino acids 19-210 of SEQ ID NO:4; (i) a nucleic acid sequence that encodes a protein
  • Fig. 13 shows Survivin-specific IFNy SFU/10 6 PBMCs from individual non human primates immunized using an embodiment of the disclosure comprising synthetic consensus Survivin 1T3 with a low dose of IL-12 (0.04 mg).
  • a variant may be a nucleic acid sequence that is substantially identical over the full length of the full gene sequence or a fragment thereof.
  • the nucleic acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof.
  • a variant may be an amino acid sequence that is substantially identical over the full length of the amino acid sequence or fragment thereof.
  • the nucleic acid molecule comprises SEQ ID NO: 2; a fragment comprising at least 90% of the entire length of SEQ ID NO: 2; a fragment that is at least 95% identical to SEQ ID NO: 2; or a fragment comprising at least 90% of the entire length of a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 2.
  • a consensus sequence was generated using the DNASTAR® Lasergene software package (version 13.0.0.357). The eight sequences listed above were imported into MegAlign and aligned using the ClustalW multiple sequence alignment program. Six of these sequences from lower animals contained an extra 11 amino acid residues at their C-terminal end that are not present in human sequences. These extra residues were omitted when generating the consensus human Survivin isoform 3 to avoid eliciting an off-target immune response in humans. After generating the human consensus Survivin isoform 3, the identical amino acid sequence between Survivin isoform 1 and 3 was removed from the consensus Survivin isoform 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2018/065529 2017-12-13 2018-12-13 Cancer vaccines targeting survivin and uses thereof Ceased WO2019118766A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU2018383664A AU2018383664B2 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting Survivin and uses thereof
BR112020011820-6A BR112020011820A2 (pt) 2017-12-13 2018-12-13 moléculas de ácido nucleico e seus usos, vetor, composições, proteínas e vacinas
KR1020207019758A KR102648079B1 (ko) 2017-12-13 2018-12-13 서바이빈을 표적으로 하는 암 백신 및 이의 용도
JP2020532715A JP7385569B2 (ja) 2017-12-13 2018-12-13 サバイビンを標的とするがんワクチンおよびその使用
EP18889469.5A EP3723793A4 (en) 2017-12-13 2018-12-13 SURVIVIN-TARGETING CANCER VACCINES AND THEIR USES
KR1020247008261A KR20240038139A (ko) 2017-12-13 2018-12-13 서바이빈을 표적으로 하는 암 백신 및 이의 용도
CN201880080439.6A CN111479583A (zh) 2017-12-13 2018-12-13 靶向存活素的癌症疫苗和其用途
MX2020006285A MX2020006285A (es) 2017-12-13 2018-12-13 Vacunas contra el cancer dirigidas a survivina y sus usos.
CA3083534A CA3083534A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting survivin and uses thereof
RU2020122872A RU2751253C1 (ru) 2017-12-13 2018-12-13 Противораковые вакцины, нацеленные на сурвивин, и их применения
MX2025004799A MX2025004799A (es) 2017-12-13 2020-07-13 Vacunas contra el cancer dirigidas a survivina y sus usos
JP2023125566A JP7659599B2 (ja) 2017-12-13 2023-08-01 サバイビンを標的とするがんワクチンおよびその使用
AU2024264712A AU2024264712A1 (en) 2017-12-13 2024-11-18 Cancer vaccines targeting survivin and uses thereof
JP2025056239A JP2025092647A (ja) 2017-12-13 2025-03-28 サバイビンを標的とするがんワクチンおよびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598267P 2017-12-13 2017-12-13
US62/598,267 2017-12-13

Publications (2)

Publication Number Publication Date
WO2019118766A2 true WO2019118766A2 (en) 2019-06-20
WO2019118766A3 WO2019118766A3 (en) 2019-09-19

Family

ID=66734396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/065529 Ceased WO2019118766A2 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting survivin and uses thereof

Country Status (11)

Country Link
US (2) US12064473B2 (enExample)
EP (1) EP3723793A4 (enExample)
JP (3) JP7385569B2 (enExample)
KR (2) KR20240038139A (enExample)
CN (1) CN111479583A (enExample)
AU (2) AU2018383664B2 (enExample)
BR (1) BR112020011820A2 (enExample)
CA (1) CA3083534A1 (enExample)
MX (2) MX2020006285A (enExample)
RU (1) RU2751253C1 (enExample)
WO (1) WO2019118766A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240038139A (ko) * 2017-12-13 2024-03-22 이노비오 파마수티컬즈, 인크. 서바이빈을 표적으로 하는 암 백신 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028165A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN120514834A (zh) 2014-03-28 2025-08-22 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
JP6912384B2 (ja) 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
EP3291842A4 (en) * 2015-05-07 2019-01-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER
WO2017048850A1 (en) * 2015-09-15 2017-03-23 Advaxis, Inc. Listeria-based immunogenic compositions and methods of use thereof in cancer prevention and treatment
KR20240038139A (ko) * 2017-12-13 2024-03-22 이노비오 파마수티컬즈, 인크. 서바이빈을 표적으로 하는 암 백신 및 이의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMI, L. ET AL.: "Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein", JOURNAL OF VIROLOGY, vol. 75, 2001, pages 10991 - 11001, XP002270897, DOI: 10.1128/JVI.75.22.10991-11001.2001
VIROLOGY, vol. 72, 1998, pages 1497 - 1503

Also Published As

Publication number Publication date
RU2751253C1 (ru) 2021-07-12
JP7659599B2 (ja) 2025-04-09
CA3083534A1 (en) 2019-06-20
CN111479583A (zh) 2020-07-31
JP2021506265A (ja) 2021-02-22
KR20240038139A (ko) 2024-03-22
KR20200096957A (ko) 2020-08-14
US20240358809A1 (en) 2024-10-31
RU2021117812A (ru) 2021-07-26
RU2021117812A3 (enExample) 2021-11-08
WO2019118766A3 (en) 2019-09-19
BR112020011820A2 (pt) 2020-11-17
EP3723793A2 (en) 2020-10-21
AU2018383664A1 (en) 2020-07-16
US20190175707A1 (en) 2019-06-13
AU2018383664B2 (en) 2024-12-05
JP7385569B2 (ja) 2023-11-22
JP2025092647A (ja) 2025-06-19
MX2025004799A (es) 2025-05-02
KR102648079B1 (ko) 2024-03-18
JP2023155245A (ja) 2023-10-20
US12064473B2 (en) 2024-08-20
MX2020006285A (es) 2020-09-17
AU2024264712A1 (en) 2024-12-05
EP3723793A4 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
AU2018383661B2 (en) Cancer vaccines targeting PRAME and uses thereof
US20240358809A1 (en) Cancer vaccines targeting survivin and uses thereof
US11986517B2 (en) Cancer vaccines targeting mesothelin and uses thereof
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
AU2018383662A1 (en) Cancer vaccines targeting MUC16 and uses thereof
RU2776949C2 (ru) Противораковые вакцины, нацеленные на сурвивин, и их применения
CA3084137A1 (en) Cancer vaccines targeting lemd1 and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18889469

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3083534

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020532715

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207019758

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018383664

Country of ref document: AU

Date of ref document: 20181213

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018889469

Country of ref document: EP

Effective date: 20200713

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020011820

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020011820

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200612

WWG Wipo information: grant in national office

Ref document number: MX/A/2020/006285

Country of ref document: MX

WWG Wipo information: grant in national office

Ref document number: 202017023980

Country of ref document: IN